The regulation of gastrointestinal (GI) tract function involves complex, dynamic interactions between the mucosal layer and its underlying mesenchyme. These interactions normally serve to maintain homeostasis but may also lead to the development of disease states under pathologic conditions1. Myofibroblasts are a subpopulation of stromal cells located subjacent to the epithelial layer that communicate in a paracrine fashion with surrounding cell subpopulations to regulate a number of critical GI tract processes that include mucosal regeneration, repair, and fibrosis2.
The 18Co cell line is an example of a human colonic myofibroblast cell line that has been widely used to study myofibroblast function because it shares many of the characteristics of primary in situ myofibroblasts. These include the protein expression of a-smooth muscle actin (α-SMA) and vimentin, as well as the expression of a number of cell surface receptors such as the epidermal growth factor receptor, or receptors for lysophosphatidic acid3,4. Because of these shared ultrastructural characteristics, as well as similarities in biologic function5, the 18Co cell line has been used extensively to study myofibroblast function in the context of many disease states such as inflammatory bowel disease or colorectal cancer3,6. However, there are inherent limitations and concerns when using a cell line. These include genotypic instability over time that differentiates cell lines from primary cells, altering the phenotype and biologic function of the cell, including growth rates and interactions with other cell populations. Cell lines also lack the normal components of the GI microenvironment (epithelial, stromal, and vascular components), which is a major limitation to its use. Therefore, the conclusions drawn from experimental cell line research requires further validation to reduce the risk of misinterpretation.
Primary myofibroblasts can be obtained from human and mouse colon tissue to confirm experimental findings identified in a cell line7. The method was originally described by Mahida, et al.8, and our protocol is one of many well-described techniques that can be used to isolate primary myofibroblasts from mouse and human colon9. For any mouse model of colonic disease, this technique can be used to isolate primary myofibroblasts to study how they interact with neighboring cells or contribute to both normal or pathologic GI processes10,11. This technique can be used to study how myofibroblasts contribute to mucosal healing, fibrosis, and the development of colorectal adenomas and carcinomas. Primary myofibroblasts can also be obtained from human colon tissue that has been resected at the time of operation for benign (inflammatory bowel disease, strictures, diverticulitis) or malignant conditions. Isolated primary cells from human and mouse colon tissue can be grown in cell culture and utilized over a limited number of passages.